electroCore Stock
electroCore develops neuromodulation therapies for the non-invasive treatment of diseases and disorders.
Sign up today and learn more about electroCore Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About electroCore Stock
electroCore LLC is a U.S.-based neuroscience and bioelectronic medicine healthcare technology company dedicated to improving patient outcomes through technological advancement. The company is focused on developing its proprietary non-invasive Vagus Nerve Stimulation (nVNS) therapies for the treatment of multiple conditions in neuropsychology, metabolic disorders and immunology. The company’s initial target is the treatment of primary headache, specifically migraine and cluster headache, and the associated chronic co-morbidities of gastric motility, psychiatric, sleep, and pain disorders that drive disproportionately large direct and indirect costs within the healthcare system and society.
Funding History
| November 2012 | $500K |
|---|---|
| June 2014 | $55.0M |
| August 2016 | $1.5M |
| September 2017 | $36.0M |
| November 2017 | $34.0M |
Management
Chief Medical Officer
Peter S. Staats, MD
Chief Executive Officer
Francis Amato
Global Vice President, Sales and Marketing
Dan Duhart
Vice President, Quality Assurance
Mike Romaniw
Co-Founder, Chief Science & Strategy Officer
J. P. Errico
Vice President, Scientific, Medical and Governmental Affairs
Eric Liebler
Co-Founder and Chief Technical Officer
Steve Mendez
Chief Financial Officer
Glenn S. Vraniak
Vice President, Research
Bruce J. Simon, PhD
Press
BangaloreWeekly - Jun, 27 2018
Electrocore (ECOR) Reaches New 52-Week High After Insider Buying ActivityStockNewsTimes - Jun, 27 2018
Global Health Innovation Merck Buys 166666 Shares of Electrocore LLC (ECOR) StockGlobeNewswire (press release) - Jun, 26 2018
electroCore, Inc. Announces Closing of Initial Public OfferingEquityZen Recognized As:
